Celsion Corporation (CLSN) - NASDAQ
  • Mon, Jun. 13, 4:16 PM
    • Celsion (NASDAQ:CLSN) enters into a definitive agreement with an institutional investor to sell $6M of stock or pre-funded warrants in a registered direct offering.
    • The company has agreed to sell ~4.4M shares of common stock (or pre-funded warrants) at $1.36 a share or warrant share. For each share bought, the investor will receive a Series A warrant to purchase 0.5 of a share of common, a Series C warrant to purchase one share of common and a Series D warrant to purchase 0.5 of a share of common, all at an exercise price of $1.40 per common share.
    • The Series A warrants are exercisable six months following issuance terminating 5 1/2 years following issuance, the Series C warrants are exercisable six months following issuance terminating one year following issuance while the Series D warrants are only exercisable upon the exercise of the Series C warrants. They are initially exercisable six months following issuance and terminate 5 1/2 years following issuance.
    • Closing date is June 16.
    | Mon, Jun. 13, 4:16 PM | 2 Comments
  • Mon, May 16, 8:36 AM
    • Celsion (CLSN) Q1 results: Revenues: $0.1M (unch); R&D Expense: $3.4M (-24.4%); SG&A: $1.9M (-5.0%); Operating Loss: ($5.2M) (+18.8%); Net Loss: ($5.7M) (+18.6%); Loss Per Share: ($0.24) (+31.4%); Quick Assets: $14.3M (+53.8%).
    • No guidance given.
    | Mon, May 16, 8:36 AM
  • Mon, May 16, 8:05 AM
    • Celsion (NASDAQ:CLSN): Q1 EPS of -$0.24 misses by $0.03.
    • Revenue of $0.13M (flat Y/Y) beats by $0.05M.
    • Press Release
    | Mon, May 16, 8:05 AM
  • Tue, Apr. 19, 9:17 AM
    | Tue, Apr. 19, 9:17 AM | 2 Comments
  • Wed, Mar. 30, 9:22 AM
    • Celsion Corp. (CLSN) FY15 results: Revenues: $0.5M (unch); R&D Expense: $14.7M (-2.0%); SG&A: $6.7M (-24.7%); Operating Loss: ($20.8M) (+15.8%); Net Loss: ($22.5M) (+11.8%); Loss Per Share: ($1.03) (+25.4%); Quick Assets: $9.3M (-26.8%).
    • No guidance given.
    | Wed, Mar. 30, 9:22 AM
  • Wed, Mar. 30, 8:05 AM
    | Wed, Mar. 30, 8:05 AM
  • Dec. 16, 2015, 9:14 AM
    | Dec. 16, 2015, 9:14 AM
  • Nov. 12, 2015, 6:51 AM
    • Celsion (NASDAQ:CLSN) shares will begin trading on the TASE today. Based on its market cap, it will be included in two TASE equity indexes: the TA-BlueTech and TA-Biomed.
    • Chairman, President & CEO Michael Tardugno says, "We believe that the dual listing on the TASE will help us to open a new access point for our shares in the Israeli market that is becoming a center for biomed and emerging technology companies. The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving or accessibility to Israeli investors."
    | Nov. 12, 2015, 6:51 AM | 1 Comment
  • Nov. 5, 2015, 10:40 AM
    • Celsion Corp. (CLSN -1%) Q3 results: Revenues: $0.1M (unch); R&D Expense: $2.9M (-37.0%); SG&A: $1.5M (-25.0%); Operating Loss: ($4.2M) (+37.3%); Net Loss: ($4.3M) (+37.7%); Loss Per Share: ($0.19) (+52.5%); Quick Assets: $7.6M (-40.2%).
    • No guidance given.
    | Nov. 5, 2015, 10:40 AM
  • Nov. 5, 2015, 8:06 AM
    • Celsion (NASDAQ:CLSN): Q3 EPS of -$0.19 may not be comparable to consensus of -$0.26.
    • Revenue of $0.13M (flat Y/Y) beats by $0.02M.
    | Nov. 5, 2015, 8:06 AM
  • Oct. 12, 2015, 10:44 AM
    • Thinly traded nano cap Celsion (CLSN +9.2%) moves up on a healthy 10x surge in volume in response to its announcement of positive preclinical results for its GEN-1 IL-12 immunotherapy. Specifically, the combination of GEN-1 IL-12 with Roche's (OTCQX:RHHBY +0.7%) Avastin (bevacizumab) and J&J's (JNJ +0.9%) Doxil (doxorubicin HCl liposome injection) showed a greater than 98% reduction in tumor burden compared to the combination of Avastin and Doxil alone in an ovarian cancer cell line called SKOV3 implanted into immunocompromised mice.
    • GEN-1 is an immunotherapy consisting of an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system. It is administered via an intraperitoneal (body cavity) injection.
    • The company is currently enrolling patients in a Phase 1b trial called OVATION. A Phase 1/2 combination study should commence in mid-2016.
    | Oct. 12, 2015, 10:44 AM | 1 Comment
  • Oct. 12, 2015, 9:13 AM
    | Oct. 12, 2015, 9:13 AM | 6 Comments
  • Aug. 10, 2015, 9:36 AM
    • Celsion Corp. (CLSN) Q2 results: Revenues: $0.1M (unch); R&D Expense: $3.6M (+12.5%); SG&A: $1.8M (-21.7%); Operating Loss: ($5.2M) (+18.8%); Net Loss: ($5.7M) (+14.9%); Loss Per Share: ($0.27) (+28.9%); Quick Assets: $12M (-5.5%).
    • No guidance given.
    | Aug. 10, 2015, 9:36 AM
  • Aug. 10, 2015, 8:02 AM
    • Celsion (NASDAQ:CLSN): Q2 EPS of -$0.27 beats by $0.04.
    • Revenue of $0.13M (flat Y/Y) beats by $0.02M.
    | Aug. 10, 2015, 8:02 AM | 1 Comment
  • Aug. 6, 2015, 9:27 AM
    • Thinly traded nano cap Celsion (NASDAQ:CLSN) is up 8% premarket on light volume in response to its announcement of the latest overall survival (OS) data from its Phase 3 study, called HEAT, evaluating ThermoDox in combination with radiofrequency ablation (RFA) in primary liver cancer.
    • As of July 15, treatment with the combination showed a 58% improvement in overall survival in a subgroup of subjects (n=285/701) compared to RFA alone (p=0.0198). Median OS for the ThermoDox cohort was 79 months versus 53.6 months in the RFA-only cohort.
    • A post-hoc slice-and-dice of the data showed a ThermoDox treatment effect in Chinese patients with single lesions but it was not statistically significant.
    | Aug. 6, 2015, 9:27 AM
  • Aug. 6, 2015, 9:15 AM
    | Aug. 6, 2015, 9:15 AM | 9 Comments
Company Description
Celsion Corp. engages in the provision of oncology drug development services. It operates through developing and commercializing chemotherapeutic oncology drugs based on proprietary heat-activated liposomal technology. Its products include ThermoDox, TheraPlas, and TheraSilence. The company was... More
Sector: Healthcare
Industry: Biotechnology
Country: United States